BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer

Endocrine-Related Cancer

Volumn 15, Issue 2, 2008, Pages 511-520

  Romei, Cristina ^a   Ciampi, Raffaele ^a   Faviana, Pinuccia ^a   Agate, Laura ^a   Molinaro, Eleonora ^a   Bottici, Valeria ^a   Basolo, Fulvio ^a   Miccoli, Paolo ^a   Pacini, Fuho ^b   Pinchera, Aldo ^a   Elisei, Rossella ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; PROTEIN RET; SODIUM IODIDE SYMPORTER; THYROID PEROXIDASE; THYROID TRANSCRIPTION FACTOR 1; THYROTROPIN RECEPTOR; AUTOANTIGEN; BRAF PROTEIN, HUMAN; COTRANSPORTER; IODIDE PEROXIDASE; IRON BINDING PROTEIN; MESSENGER RNA; RET PROTEIN, HUMAN; SLC2A1 PROTEIN, HUMAN; SLC2A3 PROTEIN, HUMAN; THYROTROPIN; TPO PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CYTODIAGNOSIS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUTATIONAL ANALYSIS; PAPILLARY CARCINOMA; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; THYROID CANCER; THYROID CARCINOMA; BLOOD; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; POINT MUTATION; THYROID TUMOR;

ADULT; AUTOANTIGENS; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HUMANS; IMMUNOHISTOCHEMISTRY; IODIDE PEROXIDASE; IRON-BINDING PROTEINS; MALE; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RNA, MESSENGER; SYMPORTERS; THYROID NEOPLASMS; THYROTROPIN;

EID: 45849106001     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0130     Document Type: Article

References (41)

1. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG & Filetti S 1998 Iodide symporter gene expression in human thyroid tumors. Journal of Clinical Endocrinology and Metabolism 83 2493-2496.
2. Basolo F, Molinaro E, Agate L, Pinchera A, Pollina L, Chiappetta G, Monaco C, Santoro M, Fusco A, Miccoli P et al. 2001 RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. European Journal of Endocrinology 145 599-604.
3. Braverman LE & Utiger DL 2000 In, Werner and Ingbar's the thyroid: a fundemental and clinical text. 8th edn. Lippincott, Williams & Wilkins: Philadelphia, USA.
4. Chua EL, Wu WM, Tran KT, McCarthy SW, Lauer CS, Dubourdieu D, Packham N, O'Brien CJ, Turtle JR & Dong Q 2000 Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. Journal of Clinical Endocrinology and Metabolism 85 2733-2739.
5. Ciampi R & Nikiforov YE 2007 RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148 936-941.
6. Di Cristofaro J, Silvy M, Lanteaume A, Marcy M, Carayon P & De Micco C 2006 Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes. Endocrine-Related Cancer 13 485-495.
7. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS & Carrasco N 2003 The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocrine Reviews 24 48-77.
8. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A et al. 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. Journal of Clinical Endocrinology and Metabolism 92 2840-2843.
9. Elisei R, Pinchera A, Romei C, Gryczynska M, Pohl V, Maenhaut C, Fugazzola L & Pacini F 1994 Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. Journal of Clinical Endocrinology and Metabolism 78 867-871.
10. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, Basolo F, Demidchik EP, Miccoli P, Pinchera A et al. 2001 RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. Journal of Clinical Endocrinology and Metabolism 86 3211-3216.
11. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H & Muller-Schauenburg W 1996 Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Journal of Nuclear Medicine 37 1468-1472.
12. V600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-Related Cancer 13 455-464.
13. Greene FL (Ed.) 2002 AJCC Cancer Staging Handbook. Chicago: Springer.
14. Haugen BR 1999 Management of the patient with progressive radioiodine non-responsive disease. Seminars in Surgical Oncology 16 34-41.
15. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ et al. 2006 The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clinical Endocrinology 65 364-368.
16. V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research 65 4238-4245.
17. Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW & Perrier ND 2004 Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid 14 806-812.
18. Matsuzu K, Segade F, Wong M, Clark OH, Perrier ND & Bowden DW 2005 Glucose transporters in the thyroid. Thyroid 15 545-550.
19. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M et al. 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 115 1068-1081.
20. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr, Knauf JA, Zhang L, Taira K & Fagin JA 2006 BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147 1014-1019.
21. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 88 4393-4397.
22. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H & Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research 57 1690-1694.
23. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404.
24. Powell DJ Jr, Russell J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A et al. 1998 The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Research 58 5523-5528.
25. Puxeddu E, Moretti S, Giannico A, Martinelli M, Marino C, Avenia N, Cristofani R, Farabi R, Reboldi G, Ribacchi R et al. 2003 Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. European Journal of Endocrinology 148 505-513.
26. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G et al. 2004 BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 89 2414-2420.
27. - targeting to the membrane. Endocrine-Related Cancer 13 257-269.
28. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. Journal of Clinical Endocrinology and Metabolism 91 498-505.
29. Schlumberger M, Lacroix L, Russo D, Filetti S & Bidart JM 2007 Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nature Clinical Practice. Endocrinology & Metabolism 3 260-269.
30. Smida J, Salassidis K, Hieber L, Zitzelsberger H, Kellerer AM, Demidchik EP, Negele T, Spelsberg F, Lengfelder E, Werner M et al. 1999 Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. International Journal of Cancer 80 32-38.
31. Smyth P, Finn S, Cahill S, O'Regan E, Flavin R, O'Leary JJ & Sheils O 2005 ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. International Journal of Surgical Pathology 13 1-8.
32. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22 4578-4580.
33. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML & Fusco A 1998 RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clinical Cancer Research 4 287-294.
34. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM et al. 2005 Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv 446 589-595.
35. De Vita G, Zannini M, Cirafici AM, Melillo RM, Di Laura R, Fusco A & Santoro M 1998 Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth and Differentiation 9 97-103.
36. 18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. Journal of Clinical Endocrinology and Metabolism 85 1107-1113.
37. Xing M 2005a BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262.
38. Xing M 2005b The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Clinical Endocrinology 63 263-266.
39. Xu X, Quiros RM, Gattuso P, Ain KB & Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Research 63 4561-4567.
40. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M & Nikiforov YE 2006 Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. Journal of Clinical Endocrinology and Metabolism 91 3603-3610.
41. Zou M, Shi Y & Farid NR 1994 Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer 73 176-180.